preliminary recommendation for the non-inclusion of eribulin in the treatment of soft tissue sarcoma in the PNF
preliminary recommendation for the inclusion of Potassium Citrate 1620 mg (15 mEq) tablet in the PNF.
preliminary recommendation for the inclusion of rituximab 1400 mg/ 11.7 mL solution for subcutaneous (SC) injection for the treatment of non-Hodgkin’s lymphoma
preliminary recommendation for the non-inclusion of pertuzumab for human epidermal growth factor receptor 2 (HER2)-positive breast cancer
Emtricitabine + Tenofovir Disoproxil Fumarate fixed-dose combination as Oral Pre-Exposure Prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-infection
